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peginterferon a/ribavirin for chronic
hepatitis CThe evolution of treatment for chronic hepatitis C (CHC)
has improved over the past 2 decades. Peginterferon a
(PEG-IFN)/ribavirin combination therapy has become the
standard regimen, even with rapid development of novel
direct-acting antivirals (DAAs), and remains the major
standard of care for CHC, especially in Asian countries.
Genotype-guide therapy was first introduced in 2004 in a
multicenter randomized clinical trial, with a recommended
regimen for CHC patients of weekly PEG-IFN 180 mg plus
ribavirin 1000e1200 mg or 800 mg daily, for either 48 weeks
in patients infected with hepatitis C virus (HCV) genotype
1/4, or 24 weeks in patients infected with HCV genotype 2/
3 [1]. Compared to Western countries, an even better
response to the recommended regimen in Asian countries
has been observed. In Taiwan, a higher sustained virological
response (SVR) rate for genotype 1 (76-80%) [2,3] and ge-
notype 2 (95%) was reported [4] than those of around 50%
and 80% for genotype 1 and 2, respectively in Western
countries. To improve therapeutic efficacy, clinical factors
associated with SVR were extensively explored to develop
individualized therapy. In addition to HCV genotype, the
virological factors including baseline HCV viral load and on-
treatment virological response are the most important
predictors for SVR that led to the era of response-guided
therapy (RGT) for genotype 1/4, integrating baseline HCV
viral load and viral kinetics, and genotype 2/3, integrating
viral kinetics and infection [5]. The definitions of the on-
treatment virological responses include the following. (1)
Rapid virological response (RVR): HCV RNA is polymerase
chain reaction (PCR) seronegative (< 50 IU/mL) after 4
weeks of therapy and (2) early virological response (EVR):
HCV RNA is PCR-seronegative or at  2 logs decrease of HCV
RNA from baseline after 12 weeks of therapy. The virolog-
ical response has been further subdivided into three cate-
gories: RVR, complete EVR (cEVR; without RVR, but HCV
RNA < 50 IU/mL at Week 12); partial EVR, [HCV RNA > 2
logs decrease in HCV RNA but still detectable (> 50 IU/mL)http://dx.doi.org/10.1016/j.aidm.2014.11.002
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for the Study of the Liver. Published by Elsevier Taiwan LLC. Open accessat Week 12], and breakthrough, HCV RNA is seronegative
during antiviral treatment, but reappearance before end of
treatment.
In host factors, the most important finding from the
genome-wide association study (GWAS) in Western coun-
tries and Japan reported that the genotype in the inter-
leukin (IL)-28B locus, located on the long arm of
chromosome 19 within the IFN-l gene cluster, was signifi-
cantly associated with SVR after PEG-IFN/ribavirin therapy
in 2009. The most commonly studied alleles for single
nucleotide polymorphism (SNP) are the rs12979860 and the
rs8099917 with favorable CC and TT genotype, respectively,
which are associated with a higher SVR rate than those with
unfavorable genotypes (rs12979860 CT/TT or rs8099917 GT/
GG, respectively) [6]. Among genotype 1 patients, IL-28B
genotypes are highly associated with RVR and SVR [6].
However, a recent meta-analysis has shown that IL-28B
genotype does not strongly affect SVR rate in genotype 2/
3 patients [7]. The important role of IL-28B in the predic-
tion of SVR in genotype 1 patients has been emphasized
clinically.
In the current issue of this journal, Chen et al [8] report
the impact of the IL-28B rs8099917 SNP on the response to
PEG-IFN/ribavirin RGT among naı¨ve patients infected with
HCV genotype 1, in their single hospital study from mid-
Taiwan. With 91.4% of patients with rs8099917 TT geno-
type, 52.3% and 64.1% of patients achieved an RVR and SVR,
respectively, and achieving RVR and IL-28B favorable ge-
notype were both independent predictors of SVR. The study
discussed the important issue of individualized therapy for
CHC in Taiwan. In Taiwan, the National Health Insurance
commenced in 1995 and began the current reimbursement
using PEG-IFN/ribavirin therapy by the RGT strategy for
CHC, as reported by Chen et al [8]: 24 weeks PEG-IFN/
ribavirin for patients with an RVR, 48 weeks for patients
without an RVR and with an EVR, and 16 weeks (the stop-
ping rule) for patients without an EVR [9]. It is necessary to, The Digestive Endoscopy Society of Taiwan and Taiwan Association
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and RVR and high viral load are not adequately treated for
only 24 weeks in the reimbursement criteria instead of 48
weeks. The IL-28B SNP is reported to be strongly associated
with an RVR and an SVR in the 24 weeks or 48 weeks
treatment with PEG-IFN/ribavirin in genotype-1-infected
patients [10e12]. Chen et al [8] have reported the signifi-
cant association between the IL-28B SNP and an SVR in
patients with an RVR who were treated for 24 weeks. In a
previous larger study reported by Huang et al [10] with 226
patients treated for 24 weeks, the SVR rate was similar
between different rs8099917 genotypes in patients
achieving an RVR. It is noteworthy that low HCV RNA (<
400,000 IU/mL), rather than IL-28B SNP, was the only factor
associated with an SVR in patients with an RVR [3]. A high
SVR rate (> 95%) [2] has been reported in patients with an
RVR and low viral load, which may firmly deny the signifi-
cant role of IL-28B SNP in these patients, therefore, further
clarification of the impact of the IL-28B SNP on the response
in patients with an RVR and high viral load may be
mandatory. For patients without an RVR and when on-
treatment response was not being considered, Chen et al
[8] have reported that those with rs8099917 TT genotype
had a higher SVR rate than those who carried rs8099917 TG/
GG genotype (49.1% vs. 16.7%), but the difference was not
significant. Huang et al [11] have reported the significantly
higher SVR rate in patients with rs8099917 TT genotype
compared with rs8099917 TG/GG genotype (72.6% vs.
33.3%, p Z 0.001). When the on-treatment response was
taken into account, the achievement of a cEVR became the
most important determinant of SVR and the influence of
rs8099917 genotype on treatment outcome became
nonsignificant [8,11]. For the slow-responders, Liu et al [13]
have conducted a randomized study to treat naı¨ve geno-
type-1-infected patients without RVR for 48 weeks or 72
weeks. With on-treatment virological responses at Week 8
evaluated for predicting an SVR, the role of IL-28B geno-
typing was apparent in patients with liver cirrhosis, positive
HCV RNA at Week 8, and a cEVR. Patients with rs8099917 TT
genotype can be treated for 48 weeks but not for 72 weeks
(SVR rate: 41% vs. 43%), and those with rs8099917 TG/GG
genotype cannot achieve an SVR with 48 weeks therapy and
have to be treated for 72 weeks (0% vs. 43%) [13].
For Taiwanese patients chronically infected with HCV
genotype 1, the approved new DAAs are boceprevir and
telaprevir in 2014. Before other new generations of DAAs
and regimens (such as IFN-free) are available, to explore
the individualized therapy for boceprevir is important and
urgent. With consideration of the combination of viral ki-
netics with or without IL-28B genotyping, Yu et al [14] and
Huang et al [15] have recommended a new “rapid stopping
rule” at Week 4: for patients with HCV RNA level decline <
3 log IU/mL, and patients carrying IL-28B unfavorable ge-
notype with HCV RNA level either > 10,000 IU/mL or
decline < 3 log IU/mL, predicting a poor response to PEG-
IFN/ribavirin dual therapy, may consider boceprevir/PEG-
IFN/ribavirin triple therapy. Further efforts have to be
made to optimize the response to PEG-IFN-based therapy,
by exploring the roles of on-treatment virological
response, IL-28B SNP, or other predictors, for Taiwanese
patients.Conflicts of interest
The author declares no conflicts of interest.
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